Skip to main content
Premium Trial:

Request an Annual Quote

Eisai Gains Access to Forma's Drug Screening Technology

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Eisai and Forma Therapeutics on Wednesday announced a collaboration for use of Forma's screening technology to support new drug development in Eisai's pipeline.

Under the terms of the deal, the US subsidiary of Japanese drug manufacturer Eisai, will have non-exclusive access to Forma's Diversity Oriented Synthesis chemistry-generated compound library and cell-based screening platforms. Eisai also has a technology transfer option for Forma's cell-based screening platform.

In return, Forma will receive upfront payments and committed funding of $20 million over three years. It is also eligible for milestone payments and royalties on future products that Eisai commercializes based on the partnership.

In a statement, Steven Tregay, CEO of Cambridge, Mass.-based Forma, said the agreement provides the firm with "significant, additional financial flexibility to pursue our internal drug discovery and development programs in oncology."

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.